Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04869020 · ClinicalTrials.gov registry record · NA
Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting
A NA study of Vertigo, sponsored by Otolith Labs.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04869020: Completed NA study of Vertigo, sponsored by Otolith Labs.
NCT04869020 is a NA study of Vertigo that has completed, run by Otolith Labs. The registered enrollment target is 40 participants, below the 16,106-participant average among 5 other Vertigo trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04869020, a NA study of Vertigo, has completed, sponsored by Otolith Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices. The study is designed to be conducted remotely using video conferencing between representatives of the manufacturer of the Otoband and participants. In order to comply with requirements for non-essential contact due to the Covid-19 pandemic there will be no person to person contact in the study.
Primary Outcome
The primary endpoint will be the change in vertigo severity rating while wearing the OtoBand compared to the change vertigo severity while wearing the sham device during the worst, most intense episode of vertigo within each treatment period (sham versus OtoBand device).
Conditions Studied
Interventions
- DEVICE Otoband
- DEVICE Sham A
- DEVICE Sham B
Study Locations (1)
District of Columbia
- Otolith Labs - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2022-11-26 |
| Phase | NA |
What the finished NCT04869020 record still lists
NCT04869020 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 16,106-participant average among 5 other Vertigo trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Vertigo appearing as the primary indexed condition, and to 3 interventions - of which Otoband is the first listed.
NCT04869020 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT04869020 about?
NCT04869020 is a clinical study titled "Evaluation of the OtoBand in Subjects With Self-reported Vertigo to Reduce Severity of Vertigo in a Real-world Setting". This study seeks to gather data on the effect of a device, the OtoBand, in participants who have reported symptoms of vertigo, compared to the effect of using one of two sham devices. The study is designed to be conducted remotely using video conferencing between representatives of the manufacturer ...
What is the current status of trial NCT04869020?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-04-19. Estimated completion is 2022-11-26.
What conditions does trial NCT04869020 study?
This clinical trial studies the following conditions: Vertigo.
What interventions are being tested in trial NCT04869020?
The interventions under investigation include: Otoband (DEVICE), Sham A (DEVICE), Sham B (DEVICE).
Who is sponsoring clinical trial NCT04869020?
This trial is sponsored by Otolith Labs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04869020 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vertigo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
RECRUITING · NA
-
Reducing Vertigo Associated With MRI Machines
RECRUITING · NA
-
Implementation of Evidence-Based Practice for Dizziness
ACTIVE NOT RECRUITING · NA
-
Gaze and Postural Stability in Multiple Sclerosis
COMPLETED · NA
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI